Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma.
Greenfield DM et al. Bone Marrow Transplant. 2014 May 19. doi: 10.1038/bmt.2014.103. [Epub ahead of print].
Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture: a clinical perspective.
Bours SP et al. Curr Opin Rheumatol. 2014 May 17. [Epub ahead of print].
Optic nerve and dura mater involvement as the first sign of multiple myeloma.
Yilmaz SG et al. Eur J Ophthalmol. 2014 May 12:0. doi: 10.5301/ejo.5000489. [Epub ahead of print].
Cutaneous involvement by multiple myeloma.
Kubica AW et al. Am J Hematol. 2014 May 15. doi: 10.1002/ajh.23761. [Epub ahead of print].
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ et al. Br J Haematol. 2014 May 14. doi: 10.1111/bjh.12925. [Epub ahead of print].
Central pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging study.
Boland EG et al. PLoS One. 2014 May 12;9(5):e96474. doi: 10.1371/journal.pone.0096474. eCollection 2014.
Complex hypodiploid acute myeloid leukaemia secondary to chemotherapy for hyperdiploid multiple myeloma.
Mohamed M et al. Int J Hematol. 2014 May 13. [Epub ahead of print].
Partial Tumor Resection Combined with Chemotherapy for Multiple Myeloma Spinal Cord Compression.
Qian J et al. Ann Surg Oncol. 2014 May 13. [Epub ahead of print].
Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.
Ji B et al. Int j numer method biomed eng. 2014 May 9. doi: 10.1002/cnm.2645. [Epub ahead of print].
Nitrogen Bisphosphonate-induced Orbital Inflammatory Disease: Gamma Delta T Cells-A Report and Review of 2 Cases.
Vora MM et al. Ophthal Plast Reconstr Surg. 2014 May 8. [Epub ahead of print].
Cloudy corneas as an initial presentation of multiple myeloma.
Sharma P et al. Clin Ophthalmol. 2014 Apr 28;8:813-7. doi: 10.2147/OPTH.S49283. eCollection 2014.
Solitary necrobiotic xanthogranuloma of an upper extremity in association with multiple myeloma.
Bain Iii EE et al. J Drugs Dermatol. 2014 May 1;13(5):598-600.
The Role of Bisphosphonates in Medical Oncology and Their Association with Jaw Bone Necrosis.
Eid A et al. Oral Maxillofac Surg Clin North Am. 2014 May;26(2):231-237. doi: 10.1016/j.coms.2014.01.009.
The graft-versus-myeloma effect: Chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
Donato ML et al. Biol Blood Marrow Transplant. 2014 Apr 30. pii: S1083-8791(14)00267-5. doi: 10.1016/j.bbmt.2014.04.027. [Epub ahead of print].
Myeloma progression and urinary gammaglobulin affect the urinary cystatin C to diagnose acute kidney injury in multiple myeloma.
Kim JS et al. Clin Nephrol. 2014 May;81(5):345-9.
A case of protothecosis in a patient with multiple myeloma.
Figueroa CJ et al. J Cutan Pathol. 2014 May;41(5):409-13. doi: 10.1111/cup.12338.
Muscular Relapse in a Patient With Multiple Myeloma.
Waheed S et al. J Clin Oncol. 2014 Apr 28. [Epub ahead of print].
Isolated orbital relapse of multiple myeloma in a patient with severe chronic GVHD after allogeneic hematopoietic SCT.
Blecha C et al. Bone Marrow Transplant. 2014 Apr 28. doi: 10.1038/bmt.2014.81. [Epub ahead of print].